JP2023550191A5 - - Google Patents

Info

Publication number
JP2023550191A5
JP2023550191A5 JP2023531563A JP2023531563A JP2023550191A5 JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5 JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5
Authority
JP
Japan
Prior art keywords
nanocage
fusion protein
monomer
subunit
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051690 external-priority patent/WO2022109743A1/en
Publication of JP2023550191A publication Critical patent/JP2023550191A/ja
Publication of JP2023550191A5 publication Critical patent/JP2023550191A5/ja
Pending legal-status Critical Current

Links

JP2023531563A 2020-11-25 2021-11-25 Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 Pending JP2023550191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2023550191A JP2023550191A (ja) 2023-11-30
JP2023550191A5 true JP2023550191A5 (https=) 2024-12-02

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531563A Pending JP2023550191A (ja) 2020-11-25 2021-11-25 Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法

Country Status (9)

Country Link
US (1) US20240182544A1 (https=)
EP (1) EP4251654A4 (https=)
JP (1) JP2023550191A (https=)
KR (1) KR20230116833A (https=)
CN (1) CN116917339A (https=)
AU (1) AU2021386892A1 (https=)
CA (1) CA3202378A1 (https=)
MX (1) MX2023006148A (https=)
WO (1) WO2022109743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
KR20250135167A (ko) * 2022-09-11 2025-09-12 래디언트 바이오테라퓨틱스 인크. 다중체를 사용하는 화학요법-내성 종양의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195626B (zh) * 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
JP2022529512A (ja) * 2019-04-25 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗体で修飾した自己集合するタンパク質ナノケージ（ｓａｐｎａ）及びその部分

Similar Documents

Publication Publication Date Title
JP6104121B2 (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP2024504777A5 (https=)
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
EP3356420B1 (en) Multispecific antibodies
JP6853250B2 (ja) 抗体の挿入可能な可変フラグメント及びｎｋｇ２ｄリガンドの改変されたａ１−ａ２ドメイン、及び非天然のｎｋｇ２ｄ受容体に結合する非天然のｎｋｇ２ｄリガンド
EP3576789B1 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
JP2023504914A5 (https=)
AU2019398214B2 (en) Fusion protein constructs for complement associated disease
JP7583411B2 (ja) Ｆｃ領域改変抗体の精製方法
JP2020517287A5 (https=)
JP2023544211A5 (https=)
JP2019533441A5 (https=)
CN118063619A (zh) 工程化的异源二聚体蛋白质
JP2018515085A5 (https=)
JP2019519527A (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
JP2021512159A5 (https=)
JP2020505919A5 (https=)
JP2022512234A5 (https=)
JP2023553697A5 (https=)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2025160405A (ja) 特異的結合分子
JP2023550191A5 (https=)
CN108473571A (zh) 结合人Fc受体的融合蛋白
JP2019505565A5 (https=)
JPWO2022224997A5 (https=)